Passage BIO (PASG) Operating Expenses (2019 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Passage BIO was $38.09 million, down 29.9% year-over-year; for FY2025, it was $43.15 million, down 33.8% from FY2024.

• Annual Operating Expenses has declined for four consecutive years, with a five-year compound annual growth rate of -17.4% (FY2020 to FY2025).
• In prior years, Passage BIO's Operating Expenses was $65.17 million in FY2024 (-36.7%), $103 million in FY2023 (-23.9%), $135.39 million in FY2022 (-23.8%) and $177.73 million in FY2021 (+58.8%).
• Quarterly Operating Expenses has run from a low of $8.66 million in Q3 2025 to a high of $50.16 million in Q4 2021 over five years.
• On a year-over-year basis, Operating Expenses has declined in each of the last 17 quarters, with an average decline of 28.3% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 45.3%; the weakest was Q1 2024, with a decline of 49.7%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $8.88 million (Q1 2026), $10.34 million (Q4 2025) and $8.66 million (Q3 2025).